MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Stan Smith Acquires 57,189 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 57,189 shares of the stock in a transaction dated Monday, December 22nd. The stock was purchased at an average price of $1.22 per share, with a total value of $69,770.58. Following the completion of the acquisition, the director directly owned 1,421,478 shares in the company, valued at approximately $1,734,203.16. The trade was a 4.19% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Stan Smith also recently made the following trade(s):

• On Friday, December 5th, Stan Smith purchased 13,740 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.20 per share, for a total transaction of $16,488.00.
• On Tuesday, November 25th, Stan Smith acquired 15,000 shares of MAIA Biotechnology stock. The stock was purchased at an average cost of $0.98 per share, for a total transaction of $14,700.00.
• On Monday, November 24th, Stan Smith bought 10,000 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $0.99 per share, for a total transaction of $9,900.00.
• On Wednesday, October 1st, Stan Smith purchased 19,230 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.30 per share, for a total transaction of $24,999.00.

MAIA Biotechnology Stock Performance

MAIA opened at $1.36 on Wednesday. The stock’s fifty day moving average is $1.21 and its 200-day moving average is $1.50. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $2.74. The company has a market capitalization of $50.36 million and a PE ratio of -1.86.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). On average, equities research analysts forecast that MAIA Biotechnology, Inc. will post -1.3 EPS for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently bought and sold shares of MAIA. Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after acquiring an additional 505,150 shares during the last quarter. Jane Street Group LLC bought a new stake in MAIA Biotechnology in the second quarter valued at about $52,000. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at approximately $29,000. Centerpoint Advisory Group bought a new stake in MAIA Biotechnology in the second quarter valued at $28,000. Finally, Geode Capital Management LLC increased its position in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares in the last quarter. 5.65% of the stock is currently owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.